On 6 October, TauRx published a press release outlining the results of their Phase 3 Alzheimer’s Disease Study, LUCIDITY, for their new treatment Hydromethylthionine mesylate (HMTM).
In the press release, TauRx said that treatment with HMTM resulted in sustained improvement in cognition and normalisation of brain atrophy in those with early Alzheimer’s disease. For those with mild to moderate Alzheimer’s disease, the treatment was proposed to stabilise cognition and function and reduce brain atrophy.
HMTM is an oral treatment which seeks to address the accumulation of Tau; this contrasts to some other treatments which are currently in development which tackle amyloid plaques in the brain.
Unexpectedly, the placebo (control) used in the study was shown to have a clinical effect, as such TauRx have performed an alternative analysis of the data.
TauRx are scheduled to present their Phase 3 findings at the Clinical Trials in Alzheimer’s Disease (CTAD) conference, later in 2022.
ADI will continue to monitor developments and will provide relevant updates as and when they occur.